Nord/LB Analysts Give Stada Arzneimittel (ETR:SAZ) a €74.40 Price Target

Nord/LB set a €74.40 ($91.85) price objective on Stada Arzneimittel (ETR:SAZ) in a research report report published on Friday, March 23rd. The firm currently has a sell rating on the stock.

Several other equities research analysts have also recently weighed in on SAZ. Warburg Research set a €74.40 ($91.85) target price on Stada Arzneimittel and gave the stock a sell rating in a report on Wednesday, December 20th. Independent Research set a €89.00 ($109.88) price objective on Stada Arzneimittel and gave the stock a neutral rating in a research note on Wednesday, December 20th. Commerzbank set a €66.25 ($81.79) price objective on Stada Arzneimittel and gave the stock a sell rating in a research note on Wednesday, December 20th. Finally, Cfra set a €70.00 ($86.42) price objective on Stada Arzneimittel and gave the stock a sell rating in a research note on Monday, March 12th. Five investment analysts have rated the stock with a sell rating and two have given a hold rating to the company. The stock has an average rating of Sell and a consensus price target of €73.49 ($90.73).

How to Become a New Pot Stock Millionaire

Shares of SAZ stock traded down €0.38 ($0.47) during mid-day trading on Friday, hitting €83.90 ($103.58). The stock had a trading volume of 26,526 shares, compared to its average volume of 51,761. Stada Arzneimittel has a 12-month low of €53.41 ($65.94) and a 12-month high of €90.24 ($111.41).

COPYRIGHT VIOLATION NOTICE: “Nord/LB Analysts Give Stada Arzneimittel (ETR:SAZ) a €74.40 Price Target” was first published by Week Herald and is the property of of Week Herald. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://weekherald.com/2018/04/17/nord-lb-analysts-give-stada-arzneimittel-saz-a-74-40-price-target.html.

About Stada Arzneimittel

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux.

Analyst Recommendations for Stada Arzneimittel (ETR:SAZ)

Receive News & Ratings for Stada Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stada Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply